Oramed Pharmaceuticals (ORMP) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Oramed Pharmaceuticals (ORMP) has outperformed Entrada Therapeutics (TRDA) over the past year, gaining 82.5% versus a loss of 25.6%. Entrada Therapeutics is the larger company by market cap ($170.2 million vs $169.3 million), about 1.0 times the size. Oramed Pharmaceuticals converts more of its revenue into profit, with a net margin of 3202.5% versus -565.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORMP | TRDA |
|---|---|---|
| Share price | $4.07 | $4.37 |
| Market cap | $169.30M | $170.15M |
| 1-day change | -2.63% | -8.58% |
| YTD return | +42.81% | -57.49% |
| 1-year return | +82.51% | -25.55% |
| 5-year return | -82.00% | — |
| P/E ratio (TTM) | 0.99 | — |
| EPS (TTM) | $4.13 | $-3.96 |
| Dividend yield | 6.13% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.00M | $25.42M |
| Revenue growth (YoY) | — | -87.94% |
| Net income (latest FY) | $64.05M | $-143.75M |
| Gross margin | 0.65% | — |
| Operating margin | -754.40% | -621.13% |
| Net margin | 3202.50% | -565.48% |
| 52-week high | $5.47 | $16.45 |
| 52-week low | $2.09 | $4.11 |
| Distance from 52-week high | -25.59% | -73.43% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +71.99% | +334.78% |
| Average volume | 188.22K | 355.10K |
| Shares outstanding | 41.60M | 38.94M |
| Employees | — | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORMP has outperformed TRDA by 108.1 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (6.13% vs 0.00%).
- Oramed Pharmaceuticals is more profitable, keeping 3202.5 cents of every revenue dollar as net income versus -565.5 cents for Entrada Therapeutics.
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
ORMP vs TRDA FAQ
Which is bigger, Oramed Pharmaceuticals or Entrada Therapeutics?
Entrada Therapeutics (TRDA) is larger, with a market capitalization of $170.15M compared with $169.30M for Oramed Pharmaceuticals (ORMP).
Which stock has performed better over the past year, ORMP or TRDA?
ORMP returned +82.51% over the past 12 months, compared with -25.55% for TRDA (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Oramed Pharmaceuticals or Entrada Therapeutics?
Oramed Pharmaceuticals pays a dividend yielding 6.13%, while Entrada Therapeutics does not currently pay a regular dividend.
Are Oramed Pharmaceuticals and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.